Company intelligence / Profile preview
Sterling-Winthrop Research Institute
Rensselaer, New York, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Sterling-Winthrop Research Institute was the primary R&D division of Sterling Drug Inc. It was responsible for the development of several historically significant drugs, including the first quinolone antibiotic (nalidixic acid), the analgesics pentazocine and meperidine, and the inotropic agents amrinone and milrinone. The institute and its parent company were acquired by Eastman Kodak in 1988 and subsequently divested in 1994, with assets split primarily between Sanofi and SmithKline Beecham.
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
SanofiEastman Kodak
Beyond the preview
Go deeper on Sterling-Winthrop Research Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sterling-Winthrop Research Institute.